Skip to main content
Terug
CNC logo

Centene Corporation

Datakwaliteit: 100%
Oversold
CNC
NYSE Healthcare Medical - Healthcare Plans
€ 32,72
▼ € 0,26 (-0,79%)
Marktkapitalisatie: 16,09B
Dagbereik
€ 31,77 € 33,62
52-Weeksbereik
€ 25,08 € 66,03
Volume
6.472.450
50D / 200D Gem.
€ 41,89 / € 37,93
Vorige Slotkoers
€ 32,98

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -2,4 0,2
P/B 0,8 3,0
ROE % -28,8 3,6
Net Margin % -3,4 3,8
Rev Growth 5Y % 11,5 9,7
D/E 0,9 0,2

Koersdoel Analisten

Hold
€ 44,90 +37.2%
Low: € 38,00 High: € 59,00
Forward K/W
10,97
Forward WPA
€ 2,98
WPA Groei (sch.)
+0,0%
Omzet Sch.
189,80B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 8,79
€ 8,42 – € 9,22
 200,38B 1
FY2029 € 8,23
€ 7,88 – € 8,63
 196,32B 1
FY2028 € 5,61
€ 5,29 – € 6,01
 195,76B 3

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-06 -€ 1,22 -€ 1,19 +2,5%
2025-10-29 -€ 0,14 € 0,50 +445,4%
2025-07-25 € 0,11 -€ 0,16 -243,4%
2025-04-25 € 2,52 € 2,90 +15,1%
2025-02-04 € 0,44 € 0,80 +81,8%
2024-10-25 € 1,33 € 1,62 +21,8%
2024-07-26 € 2,07 € 2,42 +16,9%
2024-04-26 € 2,08 € 2,26 +8,7%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 11,51% annually over 5 years — strong growth
Earnings declined -301,91% over the past year
Generating 4,32B in free cash flow
PEG of 0,01 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7,93%
Capital efficient — spends only 0,39% of revenue on capex

Groei

Revenue Growth (5Y)
11,51%
Revenue (1Y)19,44%
Earnings (1Y)-301,91%
FCF Growth (3Y)-22,82%

Kwaliteit

Return on Equity
-28,79%
ROIC-14,75%
Net Margin-3,43%
Op. Margin-3,91%

Veiligheid

Debt / Equity
0,94
Current Ratio1,68
Interest Coverage-11,24

Waardering

P/E Ratio
-2,41
Forward P/E10,97
P/B Ratio0,81
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 19,44% Revenue Growth (3Y) 12,46%
Earnings Growth (1Y) -301,91% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 11,51% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 194,78B Net Income (TTM) -6,67B
ROE -28,79% ROA -8,59%
Gross Margin 12,24% Operating Margin -3,91%
Net Margin -3,43% Free Cash Flow (TTM) 4,32B
ROIC -14,75% FCF Growth (3Y) -22,82%
Safety
Debt / Equity 0,94 Current Ratio 1,68
Interest Coverage -11,24
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,41 Forward P/E 10,97
P/B Ratio 0,81 P/S Ratio 0,08
PEG Ratio 0,01 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA 4,20
Forward P/S 0,08 Fwd Earnings Yield 9,12%
FCF Yield 26,85%
Market Cap 16,09B Enterprise Value 16,98B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 194,78B 163,07B 154,00B 144,55B 125,98B
Net Income -6,67B 3,31B 2,70B 1,20B 1,35B
EPS (Diluted) -13,62 6,31 4,95 2,07 2,28
Gross Profit 23,83B 16,83B 17,32B 16,66B 14,20B
Operating Income -7,62B 3,18B 2,93B 1,32B 1,78B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 77,66B 82,45B 84,64B 76,87B 78,38B
Total Liabilities 57,61B 55,94B 58,69B 52,63B 51,35B
Shareholders' Equity 19,95B 26,41B 25,84B 24,06B 26,80B
Total Debt 18,78B 19,43B 18,88B 21,33B 22,66B
Cash & Equivalents 17,89B 14,06B 17,19B 12,07B 13,12B
Current Assets 35,99B 38,00B 40,76B 30,13B 28,50B
Current Liabilities 21,48B 34,26B 36,72B 28,46B 25,77B

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#433 of 619
22

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026